- Home
- SABA vs IKT Comparison
SABA vs IKT Comparison
Compare SABA & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SABA | IKT |
|---|---|---|
| Founded | 1988 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 225.6M | 240.1M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SABA | IKT |
|---|---|---|
| Price | $8.41 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 53.3K | ★ 722.6K |
| Earning Date | 01-01-0001 | 03-26-2026 |
| Dividend Yield | ★ 12.91% | N/A |
| EPS Growth | N/A | ★ 57.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.96 | $1.33 |
| 52 Week High | $9.46 | $2.26 |
Technical Indicators
Market Signals| Indicator | SABA | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 50.16 | 42.89 |
| Support Level | $8.24 | $1.62 |
| Resistance Level | $8.68 | $1.74 |
| Average True Range (ATR) | 0.12 | 0.12 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 45.16 | 27.50 |
Price Performance
Historical ComparisonAbout SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.